ArticleHGG advances2026
S4-multi: Enhancing polygenic score prediction in ancestrally diverse populations.
Article in HGG advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Protocol for constructing multi-ancestry polygenic models using S4-Multi.STAR protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polygenic scores (PGSs) have shown promise in advancing precision medicine by capturing the additive effects of common genetic variants to assess inherited disease risk. However, their predictive accuracy remains limited in non-European populations. We enhanced our previously developed Bayesian polygenic model, "select and shrink with summary statistics" (S4), by introducing a multi-ancestry extension (S4-Multi) to improve prediction accuracy across African, American, East Asian, European, and South Asian ancestries. By leveraging simulated data and biobank cohorts from UK Biobank, FinnGen, Biobank Japan, the All of Us Research Program, and the Global Biobank Meta-Analysis Initiative, we benchmarked S4-Multi against leading methods for predicting type 2 diabetes, breast cancer, colorectal cancer, asthma, and stroke. In simulation tests, S4-Multi outperformed its single-ancestry version, achieving over 1.6 times greater accuracy in non-European populations, and matched or exceeded top-performing methods across all tested ancestry groups. In biobank tests, S4-Multi matched the performance of the best methods, varying by ancestry and phenotype. We find that S4-Multi achieves comparable performance using 9%-77% fewer genetic variants than competing models, highlighting potential for robust performance in clinical settings with limited available genomic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.